New invention on vaccine kills cancer cells

A study by Canadian scientists has brought good news to many patients with cancer.

The new vaccine called DPX-0907 is able to safely treat diseases such as breast cancer, ovarian cancer and prostate cancer, which are currently being tested and developed at a regional hospital. Northern Italy.

The reporter in Canada led the February 6 announcement of Immunovaccine Inc. Biotechnology Company. Based in Halifax, the company has signed an agreement with researchers at Busto Arsizio Hospital in Northern Italy to test and continue developing the DPX-0907 vaccine .

According to research experts, the DPX-0907 is part of a new approach called cancer treatment vaccine . This vaccine works to help patients fight disease, not to prevent disease. DPX-0907 has the ability to stimulate the body's immune system for finding and destroying cancer cells in patients with ovarian, breast and prostate cancers.

Genevieve Weir, director of the research project, said it was a rather unique vaccine, containing seven different antigens that could target seven different pathways of cancer. She said: "The vaccine stays in the body for only about 2 weeks, but has a long-lasting immune response and can be sustained for years. Combining 7 types of antigens, DPX-0907 capable of attacking the destruction of cancer cells through multiple paths, minimizing the possibility of these cells escaping the effects of a single antigen ".

Although not involved in the DPX-0907 study, Dr. Neil Berinstein, an oncologist from Sunnybrook Toronto Hospital, also confirmed that this is an important advance. Creating an immune system targeting specific cells may be a better approach to traditional cancer treatments, killing cancer cells more than necessary. He said: "One of the values ​​of cancer immunotherapy is the direct impact against cancer cells, while the rest of the body remains intact and not subject to effects of side effects through chemotherapy and radiation ".

The first test phase of the DPX-0907 vaccine was performed in patients with breast cancer, ovarian cancer and prostate cancer. The results of the study published in the Translational Medicine Journal show that the DPX-0907 is safe and well tolerated by patients. The next phase of the study will be carried out in Italy, with an expected span of about a year, which could determine exactly how the vaccine will affect the body's immune system for Other types of cancer.